Previous Close | 66.02 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's Range | 66.02 - 66.02 |
52 Week Range | 66.02 - 66.02 |
Volume | |
Avg. Volume | N/A |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The latest investor updates on stocks that are trending on Friday.
Haleon plc ("Haleon") (LSE:HLN)(NYSE:HLN) today announced that its wholly-owned subsidiary GSK Consumer Healthcare Capital US LLC (the "Issuer") is exercising its option to redeem the total outstanding aggregate principal amount of its Callable Floating Rate Senior Notes due 2024 (the "Notes") on March 24, 2023 (the "Redemption Date").
The GSK group posted an 18% rise in sales to £7.8bn over the third quarter.
Jay Powell sounded hawkish on the outlook for rate rises from the central bank.
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants. Tuesday's news came days after shares of GlaxoSmithKline Plc, Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer. The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac.
For more than three decades, Canadians have trusted Advil to deliver relief from pain. New Advil PLUS Acetaminophen – from Haleon (formerly GSK Consumer Healthcare), a leader in pain relief – combines ibuprofen and acetaminophen to fight pain in two ways. This is the first product brought to market by Haleon since launching as an independent company focused entirely on consumer healthcare.
The drugs giant reported a 19% rise in total sales, reaching £6.9bn, with quarterly figures beating expectations for £6.3bn.